Stoke Therapeutics Awards Discretionary Bonus to CEO Smith

Stoke Therapeutics ( (STOK) ) has provided an update.

On February 13, 2026, Stoke Therapeutics’ board approved a discretionary bonus of $697,125 for Chief Executive Officer Ian F. Smith, matching his full target annual bonus for 2025 despite his non-participation in the regular annual bonus program that year. The board based this award on the company’s strong clinical and financial performance following Smith’s appointment as interim CEO in March 2025 and permanent CEO in October 2025, as well as a determination that 2025 corporate goal achievement reached 150% of target, highlighting robust operational execution and leadership performance.

The most recent analyst rating on (STOK) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Stoke Therapeutics stock, see the STOK Stock Forecast page.

Spark’s Take on STOK Stock

According to Spark, TipRanks’ AI Analyst, STOK is a Neutral.

The score is driven primarily by improving financial performance (profitability turnaround and low leverage), partially offset by weak near-term technical momentum and a high P/E valuation. Positive corporate events around an accelerated Phase 3 timeline and supportive clinical updates provide an additional uplift.

To see Spark’s full report on STOK stock, click here.

More about Stoke Therapeutics

Stoke Therapeutics, Inc. is a biotechnology company focused on developing genetic medicines, with its operations and executive leadership evaluated against clinical and financial performance milestones. The company’s incentive structures for senior management are closely tied to the achievement of corporate goals, including progress in clinical programs and overall financial results.

Average Trading Volume: 773,051

Technical Sentiment Signal: Buy

Current Market Cap: $2.1B

See more insights into STOK stock on TipRanks’ Stock Analysis page.